Display options
Cite
Vodopivec I, Prasad S. Treatment of Susac Syndrome. Curr Treat Options Neurol. 2016;18(1):3doi: 10.1007/s11940-015-0386-x.
Vodopivec, I., & Prasad, S. (2016). Treatment of Susac Syndrome. Current treatment options in neurology, 18(1), 3. https://doi.org/10.1007/s11940-015-0386-x
Vodopivec, Ivana, and Prasad, Sashank. "Treatment of Susac Syndrome." Current treatment options in neurology vol. 18,1 (2016): 3. doi: https://doi.org/10.1007/s11940-015-0386-x
Vodopivec I, Prasad S. Treatment of Susac Syndrome. Curr Treat Options Neurol. 2016 Jan;18(1):3. doi: 10.1007/s11940-015-0386-x. PMID: 26715396.
Copy Download .nbib Format: NLM
Share it on

Curr Treat Options Neurol. 2016 Jan;18(1):3. doi: 10.1007/s11940-015-0386-x.

Treatment of Susac Syndrome.

Current treatment options in neurology

Ivana Vodopivec, Sashank Prasad

Affiliations

  1. Massachusetts Eye and Ear Infirmary, Neuro-ophthalmology Service, 243 Charles Street, Boston, MA, USA. [email protected].
  2. Department of Neurology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, USA. [email protected].
  3. Harvard Medical School, Boston, MA, USA. [email protected].
  4. Department of Neurology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, USA. [email protected].
  5. Harvard Medical School, Boston, MA, USA. [email protected].

PMID: 26715396 DOI: 10.1007/s11940-015-0386-x

Abstract

OPINION STATEMENT: Susac syndrome is a microangiopathy of the brain, retina, and cochlea. Several lines of evidence support the concept that this disease is an acquired autoimmune disorder. Prospective, randomized, controlled studies of treatments are not available because the disease is rare. Furthermore, the average period of follow-up in reported cases is short, limiting a complete understanding of the natural history of the disease. Empirical treatment strategies are therefore based upon expert recommendations and anecdotal reports of response to various immunomodulators, and the appropriate duration of therapy is not known. In our opinion, the encephalopathic form of Susac syndrome should be treated early and aggressively to avoid cognitive dysfunction and disability. Induction therapy with pulse methylprednisolone frequently proves to be inadequate. Additional agents, including intravenous immunoglobulins, intravenous cyclophosphamide, or rituximab are often necessary to induce a sustained remission. Maintenance therapy with oral glucocorticoids combined with intravenous immunoglobulins, mycophenolate mofetil, methotrexate, azathioprine, cyclophosphamide, or rituximab is typically necessary to achieve a sustained remission. Aspirin may be used as an adjunctive agent, although evidence showing efficacy is scant. The response to treatment should be closely monitored by frequent clinical examinations, brain MRI, and fluorescein angiography. Once disease remission has been established, it appears prudent to continue maintenance treatment for at least two additional years, although the real long-term risk of future relapses remains unknown. Establishing a multicenter patient registry and biorepository is essential to study the pathogenesis of the disease, further define the duration of disease, identify reliable biomarkers that aid early diagnosis and assess risk of relapse, and develop effective disease-specific therapies.

Keywords: Antiplatelet agents; Immunosuppression; Susac syndrome; Treatment

References

  1. Pediatrics. 2004 Jul;114(1):276-81 - PubMed
  2. J Neurol Neurosurg Psychiatry. 2015 May;86(5):582-4 - PubMed
  3. Am J Clin Pathol. 2011 Dec;136(6):903-12 - PubMed
  4. Curr Treat Options Neurol. 2008 Jan;10(1):67-74 - PubMed
  5. Acta Ophthalmol Scand. 2005 Dec;83(6):757-8 - PubMed
  6. J Neurol Sci. 2007 Jun 15;257(1-2):270-2 - PubMed
  7. Ann Rheum Dis. 2015 Jan;74(1):204-10 - PubMed
  8. J Neurol Sci. 2007 Jun 15;257(1-2):215-20 - PubMed
  9. Pediatr Rheumatol Online J. 2008 Jan 29;6:3 - PubMed
  10. Medicine (Baltimore). 2007 Mar;86(2):93-102 - PubMed
  11. J Neuroophthalmol. 2013 Sep;33(3):260-2 - PubMed
  12. Ophthalmology. 2011 Mar;118(3):548-52 - PubMed
  13. Stroke. 1996 Jan;27(1):149-51 - PubMed
  14. Medicine (Baltimore). 1998 Jan;77(1):12-40 - PubMed
  15. Neurol Sci. 2012 Dec;33(6):1407-10 - PubMed
  16. Neurology. 2015 Aug 18;85(7):610-8 - PubMed
  17. Arch Ophthalmol. 2012 Jun;130(6):804-6 - PubMed
  18. Neurology. 1979 Mar;29(3):313-6 - PubMed
  19. Case Rep Neurol. 2014 May 21;6(2):171-5 - PubMed
  20. J Neurol Sci. 2009 Oct 15;285(1-2):230-4 - PubMed
  21. Acta Ophthalmol Scand. 1997 Feb;75(1):107-8 - PubMed
  22. J Neurol Sci. 2006 Dec 21;251(1-2):17-22 - PubMed
  23. Nat Rev Neurol. 2013 Jun;9(6):307-16 - PubMed
  24. Ophthalmology. 1986 Sep;93(9):1148-57 - PubMed
  25. Ann Rheum Dis. 2006 Dec;65(12):1545-50 - PubMed
  26. Otol Neurotol. 2011 Oct;32(8):1198-204 - PubMed
  27. Neurology. 1994 Apr;44(4):591-3 - PubMed
  28. Otol Neurotol. 2009 Jan;30(1):34-40 - PubMed
  29. Ophthalmology. 1998 Jun;105(6):1038-44 - PubMed
  30. Mult Scler. 2012 Nov;18(11):1592-9 - PubMed
  31. Stroke. 1992 Jun;23(6):903-7 - PubMed
  32. Ophthalmology. 1994 Mar;101(3):480-9 - PubMed
  33. J Neurol Sci. 2011 Mar 15;302(1-2):126-8 - PubMed
  34. J Neurol Sci. 2015 Oct 15;357(1-2):50-7 - PubMed
  35. Eur J Neurol. 2012 Jun;19(6):800-11 - PubMed
  36. Indian J Ophthalmol. 2013 Dec;61(12):772-3 - PubMed
  37. J Neuroinflammation. 2014 Mar 08;11:46 - PubMed
  38. Arthritis Rheum. 2004 Apr;50(4):1332-7 - PubMed
  39. Stroke. 1991 Jul;22(7):933-7 - PubMed
  40. Neurology. 2001 Jul 24;57(2):334-6 - PubMed
  41. AJNR Am J Neuroradiol. 2004 May;25(5):706-13 - PubMed
  42. Mayo Clin Proc. 2001 Sep;76(9):958-60 - PubMed

Publication Types